Avacincaptad pegol

Modify Date: 2024-04-03 20:09:58

Avacincaptad pegol structure	Common Name	Avacincaptad pegol
	CAS Number	1613641-69-2	Molecular Weight	N/A
	Density	N/A	Boiling Point	N/A
	Molecular Formula	N/A	Melting Point	N/A
	MSDS	N/A	Flash Point	N/A

Use of Avacincaptad pegol

Avacincaptad pegol is a C5 complement inhibitor that may reduce inflammation-related retinal pigment epithelium (RPE) damage. Avacincaptad pegol caqn be used for the research of stargardt macular dystrophy (STGD1) and geographic atrophy (GA)[1][2].

Name	Avacincaptad pegol

Description	Avacincaptad pegol is a C5 complement inhibitor that may reduce inflammation-related retinal pigment epithelium (RPE) damage. Avacincaptad pegol caqn be used for the research of stargardt macular dystrophy (STGD1) and geographic atrophy (GA)[1][2].
Related Catalog	Research Areas >> Infection Signaling Pathways >> Immunology/Inflammation >> Complement System Research Areas >> Inflammation/Immunology
References	[1]. Rehan M Hussain, et al. Stargardt macular dystrophy and evolving therapies. Expert Opin Biol Ther. 2018 Oct;18(10):1049-1059. [2]. Glenn J Jaffe, et al. C5 Inhibitor Avacincaptad Pegol for Geographic Atrophy Due to Age-Related Macular Degeneration: A Randomized Pivotal Phase 2/3 Trial. Ophthalmology. 2021 Apr;128(4):576-586.

Description

Related Catalog

Research Areas >> Infection

Signaling Pathways >> Immunology/Inflammation >> Complement System

Research Areas >> Inflammation/Immunology

References

[1]. Rehan M Hussain, et al. Stargardt macular dystrophy and evolving therapies. Expert Opin Biol Ther. 2018 Oct;18(10):1049-1059.

[2]. Glenn J Jaffe, et al. C5 Inhibitor Avacincaptad Pegol for Geographic Atrophy Due to Age-Related Macular Degeneration: A Randomized Pivotal Phase 2/3 Trial. Ophthalmology. 2021 Apr;128(4):576-586.

No Any Chemical & Physical Properties

Avacincaptad pegol

Use of Avacincaptad pegol

Names

Avacincaptad pegol Biological Activity

Chemical & Physical Properties